Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Structure Therapeutics, Inc. Sponsored ADR (GPCR)
NASDAQ:GPCR
RESEARCH TOOLSreports
Structure Therapeutics, Inc. Sponsored ADR (GPCR) Stock Price & Analysis
498 Followers
GPCR Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$25.57 - $75.02
Previous Close$38.65
Volume705.58K
Average Volume (3M)1.19M
Market Cap
$2.20B
Enterprise Value$1.77B
Total Cash (Recent Filing)$436.45M
Total Debt (Recent Filing)$5.13M
Price to Earnings (P/E)―
Beta1.30
Next Earnings
Aug 08, 2024EPS Estimate
-$0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.31
Shares Outstanding46,621,123
10 Day Avg. Volume1,230,691
30 Day Avg. Volume1,189,281
Standard Deviation0.29
R-Squared0.27
Alpha0.13
Financial Highlights & Ratios
Price to Book (P/B)4.94
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-15.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-17.22
Forecast
1Y Price Target
$82.29Price Target Upside108.07% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Structure Therapeutics, Inc. Sponsored ADR News
Bulls Say, Bears Say
Bulls Say
Clinical DataThe 12-week Phase 2a data for GSBR-1290 shows weight loss on par with Eli Lilly's orforglipron, with a comparable tolerability profile, which could rekindle investor optimism.
Drug PotentialGSBR-1290 has best-in-class potential as both a GLP monotherapy and as a backbone for multiple small molecule therapies, making it a promising candidate in the obesity treatment market.
Strategic PartnershipAnalysts believe partnering GSBR-1290 with a global strategic player before starting Phase 2b could significantly boost GPCR's market position.
Bears Say
Clinical DataGSBR-1290 weight loss disappointed in diabetics compared to LLY’s orforglipron (~3% vs. ~6%), but was right on pace in non-diabetics (~5%).
Competitive LandscapeThe signal of oral small molecule GLP1 space getting crowded, including GILD debuting their research compound with promising preclinical profile.
Stock PerformanceShares are down more than 30% due to the diabetic data not hitting expectations, which is considered an overreaction.
---
Ownership Overview
19.15% Insiders
33.71% Mutual Funds
0.93% Other Institutional Investors
46.21% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
GPCR FAQ
What was Structure Therapeutics, Inc. Sponsored ADR’s price range in the past 12 months?
Structure Therapeutics, Inc. Sponsored ADR lowest stock price was $25.57 and its highest was $75.02 in the past 12 months.
What is Structure Therapeutics, Inc. Sponsored ADR’s market cap?
Currently, no data Available
When is Structure Therapeutics, Inc. Sponsored ADR’s upcoming earnings report date?
Structure Therapeutics, Inc. Sponsored ADR’s upcoming earnings report date is Aug 08, 2024 which is in 10 days.
How were Structure Therapeutics, Inc. Sponsored ADR’s earnings last quarter?
Structure Therapeutics, Inc. Sponsored ADR released its earnings results on May 09, 2024. The company reported -$0.19 earnings per share for the quarter, beating the consensus estimate of -$0.194 by $0.004.
Is Structure Therapeutics, Inc. Sponsored ADR overvalued?
According to Wall Street analysts Structure Therapeutics, Inc. Sponsored ADR’s price is currently Undervalued.
Does Structure Therapeutics, Inc. Sponsored ADR pay dividends?
Structure Therapeutics, Inc. Sponsored ADR does not currently pay dividends.
What is Structure Therapeutics, Inc. Sponsored ADR’s EPS estimate?
Structure Therapeutics, Inc. Sponsored ADR’s EPS estimate is -$0.23.
How many shares outstanding does Structure Therapeutics, Inc. Sponsored ADR have?
Structure Therapeutics, Inc. Sponsored ADR has 57,048,140 shares outstanding.
What happened to Structure Therapeutics, Inc. Sponsored ADR’s price movement after its last earnings report?
Structure Therapeutics, Inc. Sponsored ADR reported an EPS of -$0.19 in its last earnings report, beating expectations of -$0.194. Following the earnings report the stock price went down -7.322%.
Which hedge fund is a major shareholder of Structure Therapeutics, Inc. Sponsored ADR?
Among the largest hedge funds holding Structure Therapeutics, Inc. Sponsored ADR’s share is Driehaus Capital Management LLC. It holds Structure Therapeutics, Inc. Sponsored ADR’s shares valued at 107M.
---
Structure Therapeutics, Inc. Sponsored ADR Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$82.29 (108.07% Upside)
$82.29 (108.07% Upside)
Blogger Sentiment
Bullish
GPCR Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 1.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $5.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.1%
Last 30 Days ▼ 2.1%
Last 30 Days ▼ 2.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
8.96%
12-Months-Change
Fundamentals
Return on Equity
-29.29%
Trailing 12-Months
Asset Growth
84.85%
Trailing 12-Months
Company Description
Structure Therapeutics, Inc. Sponsored ADR
Structure Therapeutics Inc is a clinical stage global biopharmaceutical company aiming to develop and deliver novel oral therapeutics to treat a wide range of chronic diseases with unmet medical need.
---
GPCR Stock 12 Month Forecast
Average Price Target
$82.29
▲(108.07% Upside)
Technical Analysis
Best Analysts Covering GPCR
1 Year
1 Year Success Rate
5/7 ratings generated profit
1 Year Average Return
+7.64%
assigned a buy rating last month
Copying Evan Seigerman's trades and holding each position for 1 Year would result in 71.43% of your transactions generating a profit, with an average return of +7.64% per trade.
---